We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Gossamer Bio Inc (GOSS) USD0.0001

Sell:$1.28 Buy:$1.30 Change: $0.14 (12.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (12.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (12.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its product candidates include Seralutinib (GB002), GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB5121 is selected based on its central nervous system, or CNS, penetration and kinase selectivity. GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS). GB7208 is focused on undergoing preclinical testing.

Contact details

3013 Science Park Rd
United States
+1 (858) 9220718

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$293.03 million
Shares in issue:
225.41 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Faheem Hasnain
    Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Bryan Giraudo
    Chief Financial Officer, Chief Operating Officer
  • Caryn Peterson
    Executive Vice President - Regulatory Affairs
  • Christian Waage
    Executive Vice President - Technical Operations and Administration
  • Richard Aranda
    Chief Medical Officer
  • Bob Smith
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.